Nachrichten zur Sarepta Therapeutics Aktie

XFRA : AB3A: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

Regenxbio, UPenn file second patent suit against Sarepta over DMD therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review

The FDA extends the review period for Sareptas (SRPT) BLA for DMD gene therapy by almost four weeks to Jun…

Scholar Rock extends slide amid concerns over Sarepta gene therapy approval

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates

Regulatory and pipeline updates from Intercept (ICPT) and Sarepta (SRPT) lead to a decline in the share price of both…

Sarepta Therapeutics shares fall as FDA delays decision on gene ...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Shares of Sarepta Therapeutics Are Dropping Wednesday

The FDA told the company that a review of a new therapy will take nearly a month longer....…

Sarepta Stock Plunges. FDA Pushes Back Decision Date on Gene Therapy.

Investors on Wednesday seemed to take the delay as a sign that opponents of approval within the agency were winning…

Sarepta says FDA is working toward accelerated approval of its latest treatment for Duchenne muscular dystrophy

Sarepta Therapeutics Inc. SRPT said Wednesday that the U.S. Food and Drug Administration has indicated after talks with the company…

Sarepta says FDA needs more time to review muscular dystrophy drug

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Argenx, Blueprint Medicines, Sarepta likely M&A targets - analyst

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Gene-Therapy Investors Have a Powerful Ally: Patients

Surging Sarepta can thank patients families for an FDA victory....…

Sarepta Therapeutics Stock Skyrockets On FDA Surprise

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sarepta Therapeutic Shares Surge 25% Following Favorable Gene Therapy Vote; Analyst Anticipates Huge Earnings Swing In 2024

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped nearly 24% on Monday morning after a panel of experts voted last Friday…

Why Sarepta Therapeutics Stock Is Skyrocketing Today

Investors are cheering a key FDA advisory committee vote....…

Sarepta Stock Rises (SRPT) After Duchenne Muscular Dystrophy ...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

XFRA : AB3A: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Sarepta surges after FDA panel backs Duchenne gene therapy

...May 15 (Reuters) - Shares of Sarepta Therapeutics soared 29......…

For Sarepta and Muscular Dystrophy Patients, Fridays FDA Hearing Was Pivotal

A panel of outside experts said the agency should accelerate approval of a pioneering gene therapy....…

Sarepta jumps 29% after FDA panel nod for gene therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sarepta Shares Rise Premarket as FDA Panel Backs DMD Gene Therapy >SRPT

Sarepta Shares Rise Premarket as FDA Panel Backs DMD Gene Therapy >SRPT...…

Sarepta stock soars 30% premarket after FDA panel backs accelerated approval for Duchenne muscular dystrophy therapy

Sarepta Therapeutics Inc.’s stock SRPT soared 30% premarket Monday, after a U.S. Food and Drug Administration panel voted 8-6…

S&P 500 Futures Climb in Premarket Trading; Sarepta Therapeutics, Magellan Midstream Ptrs Lead

S&P 500 Futures Climb in Premarket Trading; Sarepta Therapeutics, Magellan Midstream Ptrs Lead...…

FDA advisers narrowly back accelerated approval of Sarepta gene therapy

FDA advisers vote 8-6 Friday to recommend the agency grant accelerated approval to Sarepta Therapeutics Inc.’s gene therapy for Duchenne…

Sarepta muscular dystrophy drug SRP-9001 endorsed by FDA advisors

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Advisers Back FDA Accelerated Approval for Sarepta Muscular Dystrophy Gene Therapy

Advisers Back FDA Accelerated Approval for Sarepta Muscular Dystrophy Gene Therapy...…

For Sarepta and Muscular Dystrophy Patients, Todays FDA Hearing is Pivotal

A panel of outside experts is considering whether the agency should accelerate approval of a pioneering gene therapy....…

Sarepta Therapeutics stock halted premarket ahead of FDA panel meeting on new Duchenne muscular dystrophy treatment

Sarepta Therapeutics Inc. stock SRPT was halted premarket Friday, ahead of a meeting of a Food and Drug Administration advisory…

XFRA : AB3A: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

Sarepta Duchenne gene therapy heads to FDA advisory meeting

...By Leroy Leo (Reuters) - Advisers to the U.S. Food and Drug......…

Why Sarepta Therapeutics Stock Faded This Week

The biotechs shares have turned volatile ahead of an important regulatory event....…

Sarepta on watch as FDA comments on gene therapy ahead of AdCom meeting

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product…

Sarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript

SRPT earnings call for the period ending March 31, 2023....…

Sarepta Therapeutics Q1 Loss Increases, but beats estimates

WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT) revealed Loss for its first quarter that increased from last year and missed the…

Sarepta Therapeutics Q1 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sarepta Down on Reports of FDA Almost Rejecting DMD Gene Therapy

Per a Stat News article, the FDA initially considered rejecting Sareptas (SRPT) regulatory filing seeking FDAs accelerated approval for DMD…

UPDATE 1-Sarepta drops as report says FDA almost rejected under-review gene therapy

...(Adds analysts comments, updates shares) April 13 (Reuters) - Sarepta... that may be pending. Sarepta did not respond to a Reuters request......…

Blitz-Update: Dow & Co mit Zugewinnen, Technologiewerte gefragt, Apple und Microsoft stark, Alibaba dreht ins Plus, Delta Airlines, Harley Davidson und Sarepta schwach

Konjunkturdaten haben am Donnerstag insbesondere US-Technologiewerte wieder auf Erholungskurs gebracht. So gewann der Nasdaq 100 im frühen Handel 1,38 Prozent…

dpa-AFX ProFeed